2. Epigenetics
  3. DNA Methyltransferase
  4. Levetiracetam

Levetiracetam  (Synonyms: UCB L059)

Cat. No.: HY-B0106 Purity: 99.90%
COA Handling Instructions

Molarity Calculator

Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent.

For research use only. We do not sell to patients.

Levetiracetam Chemical Structure

Levetiracetam Chemical Structure

CAS No. : 102767-28-2

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 87 In-stock
Solution
10 mM * 1 mL in DMSO USD 87 In-stock
Solid
50 mg USD 79 In-stock
100 mg USD 132 In-stock
500 mg USD 343 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Levetiracetam:

Levetiracetam Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Levetiracetam

View All DNA Methyltransferase Isoform Specific Products:

View All Isoforms
DNA Methyltransferase DNMT1 DNMT3 MGMT

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Levetiracetam, an antiepileptic agent, binds the synaptic vesicle protein SV2A. Levetiracetam enhances Temozolomide effect on glioblastoma stem cell proliferation and apoptosis. Levetiracetam modulates HDAC levels ultimately silencing MGMT, thus increasing Temozolomide effectiveness. A chemosensitizer agent[1][2].

IC50 & Target

M2 mAChR[1]
In Vitro

Levetiracetam increases the transcription of HDACs and recruits corepressor complex on O6-Methylguanine-DNA-methyltransferase (MGMT) promoter, thus silencing its activity[1].
Levetiracetam sensitizes (40 μg/mL) glioblastoma multiforme stem-like cells (GSCs) to Temozolomide (250 μM) treatment[1].
MGMT expression is downregulated in GCSCs treated with Levetiracetam (40 μg/mL)[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Levetiracetam Related Antibodies

Cell Viability Assay[1]

Cell Line: GCSC neurospheres
Concentration: 40 μg/mL
Incubation Time: 48 hours
Result: Slight antitumor effect exerted by the treatment with Temozolomide (250 µM) or Levetiracetam (40 μg/mL) alone was strongly enhanced when Temozolomide and Levetiracetam were added in combination.

Western Blot Analysis[1]

Cell Line: Glioblastoma multiforme stem-like cells (GSCs)
Concentration: 40 μg/mL
Incubation Time: 48 hours
Result: A high level of MGMT expression in untreated GCSCs; this expression was slightly decreased after treatment with Temozolomide (250 µM) and Levetiracetam singularly but it was dramatically decreased after the combined treatment with Temozolomide and Levetiracetam.
In Vivo

Levetiracetam (10, 25, or 50 mg/kg) suppresses behavioral and electrographic seizure activity during neonatal hypoxia[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Long-Evans rats[2]
Dosage: 10, 25, or 50 mg/kg
Administration: Intraperitoneal injection 60 min before hypoxia.
Result: Treatment resulted in a significant decrease in hypoxic seizure (HS) duration at 25 mg/kg and at 50 mg/kg. Anticonvulsant activity was maximal at 50 mg/kg, at which HSs were reduced by 63.6%.
Molecular Weight

170.21

Formula

C8H14N2O2
CAS No.
Unlabeled CAS

102767-28-2
Appearance

Solid

Color

White to off-white

SMILES

NC([C@@H](N(CCC1)C1=O)CC)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : ≥ 85 mg/mL (499.38 mM)

DMSO : ≥ 85 mg/mL (499.38 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 5.8751 mL 29.3755 mL 58.7510 mL
5 mM 1.1750 mL 5.8751 mL 11.7502 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (14.69 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (14.69 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (587.51 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.90%

COA (251 KB) LCMS (260 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 5.8751 mL 29.3755 mL 58.7510 mL 146.8774 mL
5 mM 1.1750 mL 5.8751 mL 11.7502 mL 29.3755 mL
10 mM 0.5875 mL 2.9375 mL 5.8751 mL 14.6877 mL
15 mM 0.3917 mL 1.9584 mL 3.9167 mL 9.7918 mL
20 mM 0.2938 mL 1.4688 mL 2.9375 mL 7.3439 mL
25 mM 0.2350 mL 1.1750 mL 2.3500 mL 5.8751 mL
30 mM 0.1958 mL 0.9792 mL 1.9584 mL 4.8959 mL
40 mM 0.1469 mL 0.7344 mL 1.4688 mL 3.6719 mL
50 mM 0.1175 mL 0.5875 mL 1.1750 mL 2.9375 mL
60 mM 0.0979 mL 0.4896 mL 0.9792 mL 2.4480 mL
80 mM 0.0734 mL 0.3672 mL 0.7344 mL 1.8360 mL
100 mM 0.0588 mL 0.2938 mL 0.5875 mL 1.4688 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Levetiracetam Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Levetiracetam102767-28-2UCB L059UCB L 059UCB L-059DNA MethyltransferaseDNMTsDNA MTasesantiepilepticsynapticvesicleproteinSV2ATemozolomide glioblastomaapoptosisHDAMGMTchemosensitizerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Levetiracetam
Cat. No.:
HY-B0106
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.